Under construction – not a live service
Sign in
Taking people in JapanNo phase

Studies aflibercept safety in Japanese people with neovascular glaucoma

Follows Japanese people with neovascular glaucoma who start aflibercept treatment in routine care.

Plain-language title generated from the registry record
Registry title: Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Key facts

Where
Multiple Locations, JapanSee the site

Where in Japan

  • Many locationsMultiple Locations, JapanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Bayer
Trial code
NCT04519619
Record updated
30 June 2026
Original description
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.Read full original descriptionShow less

Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.

The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Inclusion: Diagnosis of NVG; Patients who have received IVT-AFL treatment according to Japanese labeling.

Exclusion: Patients who are contraindicated based on approved label; Diagnosis of other indication.

ClinicalTrials.gov NCT04519619